The Asthma, COPD & Allergic Rhinitis Market Outlook to 2011

Published by: Business Insights

Published: Jul. 1, 2006 - 163 Pages

Table of Contents

Executive Summary

Patient potential

Global market analysis

Analysis of future potential respiratory blockbusters

Leading players in the respiratory market

Chapter 1 Patient potential

Summary

Introduction

Asthma

Overview

Diagnosis, treatment and management

Epidemiology

Chronic Obstructive Pulmonary Disease (COPD)

Overview

Diagnosis, treatment and management

Epidemiology

Allergic rhinitis

Overview

Diagnosis, treatment and management

Epidemiology

Chapter 2 Global market analysis

Summary

Introduction

Respiratory market analysis by drug class

Leading respiratory brand dynamics

Asthma/COPD market analysis

Introduction

Asthma/COPD drug classes

Leading brands in the asthma/COPD market

SABA/LABA therapies

Leading brands in the global SABA/LABA market

Overview/market dynamics

Key brands analysis

Inhaled corticosteroids

Leading brands in the global ICS market

Overview/market dynamics

Key brands analysis

Combination LABA/ICS products

Leading brands in the global combination LABA/ICS market

Overview/market dynamics

Key brands analysis

Leukotriene antagonists

Leading brands in the global leukotriene antagonist market

Overview/market dynamics

Key brands analysis

Anticholinergics/anticholinergics combination products

Leading brands in the global anticholinergic market

Overview/market dynamics

Key brands analysis

Asthma/COPD class forecasts to 2011

Allergic rhinitis market analysis

Introduction

Allergic rhinitis drug classes

Leading brands in the allergic rhinitis market

Anti-histamines

Leading brands in the global antihistamines market

Overview/market dynamics

Key brands analysis

Nasal corticosteroids

Leading brands in the global nasal corticosteroid market

Overview/market dynamics

Key brands analysis

Allergic rhinitis class forecasts to 2011

Chapter 3 Analysis of future potential respiratory blockbusters

Summary

Introduction

Major approaches to R&D

Drug profiles

Phase II pipeline drugs

Super Advair (fluticasone/salmeterol)

EPI-12323

Phase III pipeline drugs

QAB149 (indacaterol)

Allermist/Avamys (fluticasone furoate)

Flutiform (formoterol/fluticasone)

Drugs in registration

arformoterol

Alvesco (ciclesonide)

Daxas (roflumilast)

Ariflo (cilomilast)

Recently marketed drugs

Xolair (omalizumab)

Asmanex (mometasone)

Forecast sales potential

Chapter 4 Leading players in the respiratory market

Summary

Introduction

Global market shares

GlaxoSmithKline

Marketed products

R&D compounds

Respiratory portfolio sales forecasts to 2011

Merck & Co.

Marketed products

R&D compounds

Respiratory portfolio sales forecasts to 2011

Boehringer Ingelheim

Marketed products

R&D compounds

Respiratory portfolio sales forecasts to 2011

AstraZeneca

Marketed products

R&D compounds

Respiratory portfolio sales forecasts to 2011

Schering-Plough

Marketed products

R&D compounds

Respiratory portfolio sales forecasts to 2011

Sanofi-Aventis

Marketed products

R&D compounds

Respiratory portfolio sales forecasts to 2011

Pfizer

Marketed products

R&D compounds

Respiratory portfolio sales forecasts to 2011

Novartis

Marketed products

R&D compounds

Respiratory portfolio sales forecasts to 2011

Chapter 5 Appendix

IMS sales data

Glossary

Index

List of Figures

Figure 1.1: Estimated proportion of patients presenting with asthma that are correctly diagnosed by physician visit

Figure 1.2: Typical treatment patterns in the treatment of asthma

Figure 1.3: Typical treatment patterns in COPD

Figure 1.4: Classification of allergic rhinitis

Figure 1.5: Treatment of allergic rhinitis across different stages of disease progression

Figure 2.6: Competitive dynamics of drug classes within the global respiratory market, 2005

Figure 2.7: Competitive dynamics of leading brands in the global respiratory market, 2005

Figure 2.8: Competitive dynamics of drug classes within the global asthma/COPD market, 2005

Figure 2.9: Competitive dynamics of leading brands in the global asthma/COPD market, 2005

Figure 2.10: Competitive dynamics of drug classes within the allergic rhinitis market, 2005

Figure 2.11: Competitive dynamics of leading brands in the AR market, 2005

Figure 3.12: Leading recently launched respiratory products and compounds in R&D, 2006

Figure 3.13: Prevailing R&D approaches, 2006

Figure 4.14: Key players in the global respiratory market, 2001 & 2005

List of Tables

Table 1.1: Estimated prevalence of asthma in across seven major markets, 2005

Table 1.2: Forecast epidemiology of asthma across the seven major markets, 2005-11

Table 1.3: Estimated prevalence of COPD in across seven major markets, 2005

Table 1.4: Forecast epidemiology of COPD across the seven major markets, 2005-11

Table 1.5: Estimated prevalence of allergic rhinitis in across seven major markets, 2005

Table 1.6: Forecast epidemiology of allergy rhinitis across the seven major markets, 2005-11

Table 2.7: Breakdown of the global respiratory market by drug class, 2001-05

Table 2.8: Leading products in the global respiratory market, 2004-05

Table 2.9: Breakdown of the global asthma/COPD market by drug class, 2001-05

Table 2.10: Leading asthma/COPD products in the global respiratory market, 2004-05

Table 2.11: Leading SABA/LABA brands in the global respiratory market, 2004-05

Table 2.12: Leading ICS brands in the global respiratory market, 2004-05

Table 2.13: Leading combination LABA/ICS brands in the global respiratory market, 2004-05

Table 2.14: Leading leukotriene antagonist brands in the global respiratory market, 2004-05

Table 2.15: Leading anticholinergic brands in the global respiratory market, 2004-05

Table 2.16: Sales forecasts for classes in the asthma/COPD market, 2005-11

Table 2.17: Breakdown of the global allergy rhinitis market by drug class, 2001-05

Table 2.18: Leading allergic rhinitis products in the global respiratory market, 2004-05

Table 2.19: Leading antihistamine brands in the global respiratory market, 2004-05

Table 2.20: Leading nasal corticosteroid brands in the global respiratory market, 2004-05

Table 2.21: Sales forecasts for allergic rhinitis classes, 2005-11

Table 3.22: Sales forecasts for promising pipeline and recently launched compounds in R&D, 2005-11

Table 4.23: Key players in the global respiratory market, 2001-05

Table 4.24: GSK’s marketed respiratory portfolio, 2004-05

Table 4.25: GSK’s respiratory R&D pipeline, 2006

Table 4.26: Forecast sales for GSK’s respiratory portfolio, 2005-11

Table 4.27: Merck & Co’s marketed respiratory portfolio, 2004-05

Table 4.28: Merck & Co.’s respiratory R&D pipeline, 2006

Table 4.29: Forecast sales for Merck & Co.’s respiratory portfolio, 2005-11

Table 4.30: Boehringer Ingelheim’s marketed respiratory portfolio, 2004-05

Table 4.31: Forecast sales for BI’s respiratory portfolio, 2005-11

Table 4.32: AstraZeneca’s marketed respiratory portfolio, 2004-05

Table 4.33: AstraZeneca’s respiratory R&D pipeline, 2006

Table 4.34: Forecast sales for AstraZeneca’s respiratory portfolio, 2005-11

Table 4.35: Schering-Plough’s marketed respiratory portfolio, 2004-05

Table 4.36: Schering-Plough’s respiratory R&D pipeline, 2006

Table 4.37: Forecast sales for Schering-Plough’s respiratory portfolio, 2005-11

Table 4.38: Sanofi-Aventis’ marketed respiratory portfolio, 2004-05

Table 4.39: Sanofi-Aventis’ respiratory R&D pipeline, 2006

Table 4.40: Forecast sales for Sanofi-Aventis’ respiratory portfolio, 2005-11

Table 4.41: Pfizer’s marketed respiratory portfolio, 2004-05

Table 4.42: Pfizer’s respiratory R&D pipeline, 2006

Table 4.43: Forecast sales for Pfizer’s respiratory portfolio, 2005-11

Table 4.44: Novartis’ marketed respiratory portfolio, 2004-05

Table 4.45: Novartis’ respiratory R&D pipeline, 2006

Table 4.46: Forecast sales for Novartis’ respiratory portfolio, 2005-11

Abstract

• The global respiratory market was valued at $34.2bn in 2005, up
10.3% on $31.0bn in 2004. Growth is increasingly dependent on asthma and COPD indications, with the allergic rhinitis market suffering from a lack of innovation and high levels of generic competition.
• Sales growth in the asthma/COPD market can be deemed to be dependent on the performance of just two products, with 40.7% of total growth in 2005 being derived from leukotriene antagonist,
Singulair, and anticholinergic, Spiriva.
• The respiratory R&D pipeline is dominated by reformulations and
“me-too” products, as major players in the respiratory area attempt to emulate GSK’s success in the marketing of Seretide/Advair.
• The failure of leading companies Sanofi-Aventis, Pfizer and
Schering-Plough to evolve failing allergic rhinitis portfolios and exploit opportunities in COPD may provide the impetus for a new wave of companies to establish themselves in the respiratory market.

• What will be the major growth indications in the respiratory area over the period 2005-11?
• How does the performance of major brands in 2004 compare to that in 2005?
• How significant is the threat of generic competition to the overall performance of the asthma, COPD and allergic rhinitis markets?
• Which companies are best positioned to succeed in the global respiratory market over the period 2005-11?
• What is the forecast market size and growth rates over the period 2005-2011 across the major respiratory indications?
• Which R&D compounds are likely to make a major impact on the asthma, COPD and allergic rhinitis markets?

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.